<b>Tirzepatide Associated with Reduced Albuminuria in Participants With Type 2 Diabetes: Pooled Post Hoc Analysis From the Randomized Active- and Placebo-Controlled SURPASS-1–5 Clinical Trials</b>
Ellen M. Apperloo(Dialyse Centrum Groningen), Hiddo J.L. Heerspink(University Medical Center Groningen), Imre Pávó(Eli Lilly (United States)), David Z.I. Cherney(University Health Network), Axel Haupt(Accadis Hochschule Bad Homburg), Katherine R. Tuttle(Providence Regional Medical Center Everett), Naveed Sattar(University of Glasgow), Rebecca C. Taylor(MRC Laboratory of Molecular Biology), Andrea Hemmingway(Eli Lilly (United States)), Russell J. Wiese(Eli Lilly (United States))
Cited by 0
Related Papers
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k
Dapagliflozin in Patients with Chronic Kidney Disease
|New England Journal of Medicine|2020|5.2k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k